The Forgotten Pill That Still Fights TB in 2024
Para-aminosalicylic acid was first synthesized in 1946. Back then, tuberculosis killed millions. Antibiotics like streptomycin gave hope, but resistance emerged fast. PAA stepped in as one of the earliest oral agents effective against TB bacilli. It worked—clumsily, with side effects like gastrointestinal distress—but it worked. Fast forward to 2024, and first-line drugs like isoniazid and rifampicin dominate treatment. So why does PAA still exist? Because multidrug-resistant TB (MDR-TB) infects over 450,000 people globally every year. When those frontline drugs stop working, clinicians turn to the old guard. PAA is often on that list. It’s not preferred. It’s tolerated. But sometimes, tolerating a drug is better than watching a patient deteriorate.
The thing is, PAA doesn’t kill bacteria directly. Instead, it mimics PABA (para-aminobenzoic acid), a compound bacteria need to make folic acid. By sneaking into metabolic pathways, it jams the machinery. Human cells don’t synthesize folate the same way, so the impact on us is limited—though not harmless. We’re far from it. Nausea, vomiting, and liver enzyme elevations are common. Some patients develop hypersensitivity reactions, including fever or rash. But because TB can lie dormant for years, silently wrecking lung tissue, the trade-off is often deemed acceptable. Especially in regions with limited access to newer agents like bedaquiline, which can cost upwards of $900 per course in low-income countries.
How PAA Fits into Modern TB Therapy Protocols
Current WHO guidelines list PAA as a group C drug—meaning it’s used when stronger options aren't available or tolerated. It’s rarely the cornerstone of treatment, more of a supporting player. Patients typically take 8 to 12 grams daily, split into four doses. Compliance is a known issue. That’s 16 to 24 pills per day, depending on formulation. Imagine swallowing that many pills for 18 months—the average duration for MDR-TB treatment. No wonder adherence drops. Enter granular formulations like Paser® granules, which improve bioavailability and reduce pill burden. Still, the regimen is grueling. And that’s exactly where the human factor kicks in: medical efficacy means nothing if the patient stops halfway.
Why Compliance Determines Success More Than Chemistry
You can have the most potent drug in the world, but if people can’t or won’t take it consistently, it’s useless. PAA’s role in treatment hinges less on its mechanism and more on whether patients can endure it. In India, a 2019 study across six TB centers found that only 58% of patients on PAA-based regimens completed therapy. Side effects were the leading reason for dropout. Some clinics now pair PAA with antiemetics or stagger dosing around meals. Others use directly observed therapy (DOT), where a health worker watches each dose. It’s labor-intensive. It’s expensive. But when you’re dealing with airborne pathogens that evolve rapidly, cutting corners isn’t an option.
Side Effects: When Treatment Feels Worse Than the Disease
Let’s be clear about this: PAA is not a gentle drug. The gastrointestinal impact hits fast. Up to 70% of patients report nausea within the first week. Diarrhea follows in about half. These aren’t minor inconveniences—they disrupt work, social life, nutrition. Then there’s hepatotoxicity. Liver enzyme elevations occur in roughly 20% of users. Most are asymptomatic, but regular monitoring is non-negotiable. In rare cases, PAA triggers autoimmune reactions—like lupus-like syndrome or hypothyroidism. These are reversible upon discontinuation, but spotting them early is critical.
And then there’s the elephant in the room: drug-induced psychosis. A 2017 case report from South Africa described a 34-year-old man developing paranoia and hallucinations after six weeks on PAA. Was it the drug? Probably. Case studies like this are infrequent, but they’re real. Because mental health infrastructure is thin in many high-TB-burden countries, these symptoms often go undiagnosed. Patients get labeled “non-compliant” when they’re actually suffering. That changes everything—how we monitor, how we support, how we prescribe.
PAA vs. Newer Agents: Is Old Medicine Still Competitive?
Compare PAA to bedaquiline, delamanid, or pretomanid, and it looks like a relic. Bedaquiline, introduced in 2012, targets ATP synthase—a completely different pathway. It’s dosed once daily. Side effects? Generally milder. Cure rates? Higher. In a 2020 trial in Nepal, the BPaL regimen (bedaquiline, pretomanid, linezolid) achieved 90% success in extensively drug-resistant TB cases. PAA-based regimens hover around 60–70%. So why is PAA still in use? Cost. Availability. Infrastructure. Bedaquiline isn’t licensed in every country. Even where it is, supply chains falter. A single course may cost more than a month’s salary in Malawi. PAA, in contrast, can be produced generically for under $50. It’s not better. But it’s accessible.
Bedaquiline: The Game-Changer With Geographic Limits
Bedaquiline reduced MDR-TB mortality by 42% in clinical trials. That’s massive. Yet access remains patchy. As of 2023, only 28% of eligible patients in sub-Saharan Africa received it. Regulatory delays, procurement hurdles, outdated treatment guidelines—all slow adoption. Meanwhile, PAA remains on formularies. It’s familiar. It’s off-patent. And crucially, clinicians know how to manage its side effects. Switching to newer drugs means retraining staff, upgrading labs, investing in ECG monitoring (bedaquiline prolongs QT interval). For overstretched systems, that’s a tall order.
Linezolid: Potent but Risky in Long Courses
Linezolid works well—too well, sometimes. It’s a protein synthesis inhibitor with broad activity. But after 8 weeks, peripheral neuropathy risk jumps to 25%. Bone marrow suppression follows. PAA doesn’t cause those issues. So in long regimens, clinicians might rotate linezolid with PAA to reduce toxicity. It’s a balancing act: efficacy versus safety. There’s no perfect formula. Each case demands customization.
Frequently Asked Questions
Can PAA Be Used During Pregnancy?
Data is still lacking. Animal studies show no major teratogenic effects, but human trials are ethically unfeasible. That said, untreated TB poses a far greater risk to mother and fetus. In life-threatening cases, clinicians may use PAA under close monitoring. Folate supplementation is typically added to offset metabolic disruption. The decision isn’t taken lightly. But when alternatives are worse, it’s a risk many are willing to take.
Does PAA Interact With Other TB Medications?
Yes. It reduces the absorption of rifampicin if taken simultaneously. The fix? Dose separation—one drug in the morning, the other at night. Also, avoid antacids within two hours of PAA. Aluminum and magnesium ions bind to it, slashing bioavailability by up to 40%. Simple timing adjustments can make or break treatment success.
Is PAA Still Used in Developed Countries?
Sporadically. The U.S. CDC lists it as an option for resistant cases. But newer agents dominate. Still, outbreaks happen. In 2022, a drug-resistant TB cluster in Los Angeles involved a strain sensitive only to PAA and clofazimine. Public health teams dusted off old protocols. That’s the reality: medicine isn’t linear progress. Sometimes, you circle back.
The Bottom Line: Niche, Unpleasant, But Not Expendable
I find this overrated idea that old drugs should be discarded as medicine advances. PAA is inconvenient. It’s harsh. But in a world where 1.5 million people die from TB annually, we can’t afford purism. Eliminating PAA from global formularies would leave gaps—especially in rural clinics, conflict zones, or places with weak supply chains. Newer drugs are better, yes. But better means nothing if they aren’t there when needed. PAA is a backup. A last resort. A stubborn option when the odds are already stacked. And honestly, it is unclear whether we’ll ever fully move past it. Resistance patterns shift. Budgets shrink. Pandemics disrupt. The future of TB treatment isn’t just about innovation—it’s about resilience. PAA, for all its flaws, embodies that. That said, no one should have to rely on it in 2030. The goal isn’t to glorify outdated tools. It’s to ensure they’re no longer necessary. Until then, we keep prescribing, monitoring, adapting. Because what’s the alternative? Letting tuberculosis win. PAA tablet remains a critical tool in the fight against drug-resistant tuberculosis, even as the medical world pushes toward cleaner, simpler cures. For now, its gritty reality is part of the job.